Novo Nordisk slips after data for next-gen obesity drug
Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...
Novo Falls After New-Generation Shot Struggles in Diabetes Trial
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...
Devdiscourse52m
Novo Nordisk's CagriSema: A Weight-Loss Hopeful Under Market Scrutiny
Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...